Literature DB >> 9003389

Phosphorylation site specificity of the CDC2-related kinase PITALRE.

J Garriga1, E Segura, X Mayol, C Grubmeyer, X Graña.   

Abstract

PITALRE is a human protein kinase belonging to the cell division cycle 2 (CDC2) kinase family, and is the catalytic subunit of a multimeric complex that contains several cellular proteins. PITALRE complexes from several cell lines and tissues phosphorylate retinoblastoma protein and myelin basic protein (MBP). In the present work, we have found that MBP is phosphorylated by PITALRE complexes on both Ser and Thr residues. Two different antibodies raised to PITALRE purified virtually identical kinase activities, as analysed by MBP phosphopeptide mapping and phosphoamino acid analysis. We have identified the proline-directed residue Ser-162 of MBP as a major phosphorylation site for PITALRE. In addition, our results suggest that one of the two MBP proline-directed threonine residues, Thr-97, is also selectively phosphorylated by PITALRE. These data, together with analysis of different peptide substrates derived from sites on MBP that are phosphorylated by PITALRE, indicate that PITALRE is a Ser/Thr proline-directed kinase. In addition, our results show that PITALRE has a substrate site specificity distinguishable from those of the CDC2 and cyclin-dependent kinase 2 (CDK2).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9003389      PMCID: PMC1218024          DOI: 10.1042/bj3200983

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  20 in total

1.  Solid-phase sequencing of 32P-labeled phosphopeptides at picomole and subpicomole levels.

Authors:  R E Wettenhall; R H Aebersold; L E Hood
Journal:  Methods Enzymol       Date:  1991       Impact factor: 1.600

Review 2.  Protein kinase phosphorylation site sequences and consensus specificity motifs: tabulations.

Authors:  R B Pearson; B E Kemp
Journal:  Methods Enzymol       Date:  1991       Impact factor: 1.600

3.  Phosphorylation of large tumour antigen by cdc2 stimulates SV40 DNA replication.

Authors:  D McVey; L Brizuela; I Mohr; D R Marshak; Y Gluzman; D Beach
Journal:  Nature       Date:  1989-10-12       Impact factor: 49.962

4.  Internal amino acid sequence analysis of proteins separated by one- or two-dimensional gel electrophoresis after in situ protease digestion on nitrocellulose.

Authors:  R H Aebersold; J Leavitt; R A Saavedra; L E Hood; S B Kent
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

5.  SV40 large T antigen binds preferentially to an underphosphorylated member of the retinoblastoma susceptibility gene product family.

Authors:  J W Ludlow; J A DeCaprio; C M Huang; W H Lee; E Paucha; D M Livingston
Journal:  Cell       Date:  1989-01-13       Impact factor: 41.582

Review 6.  Cyclins and cyclin-dependent kinases: take your partners.

Authors:  J Pines
Journal:  Trends Biochem Sci       Date:  1993-06       Impact factor: 13.807

7.  Peptide mapping and purification of phosphopeptides using high-performance liquid chromatography.

Authors:  H Juhl; T R Soderling
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

8.  Identification of the sites in myelin basic protein that are phosphorylated by meiosis-activated protein kinase p44mpk.

Authors:  J S Sanghera; R Aebersold; H D Morrison; E J Bures; S L Pelech
Journal:  FEBS Lett       Date:  1990-10-29       Impact factor: 4.124

9.  Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4.

Authors:  J Kato; H Matsushime; S W Hiebert; M E Ewen; C J Sherr
Journal:  Genes Dev       Date:  1993-03       Impact factor: 11.361

10.  The function(s) of CAK, the p34cdc2-activating kinase.

Authors:  M J Solomon
Journal:  Trends Biochem Sci       Date:  1994-11       Impact factor: 13.807

View more
  11 in total

1.  E1A blocks hyperphosphorylation of p130 and p107 without affecting the phosphorylation status of the retinoblastoma protein.

Authors:  M Parreño; J Garriga; A Limón; X Mayol; G R Beck; E Moran; X Graña
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

Review 2.  P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II.

Authors:  D H Price
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

3.  P-TEFb kinase complex phosphorylates histone H1 to regulate expression of cellular and HIV-1 genes.

Authors:  Siobhan K O'Brien; Hong Cao; Robin Nathans; Akbar Ali; Tariq M Rana
Journal:  J Biol Chem       Date:  2010-06-15       Impact factor: 5.157

Review 4.  Functional evolution of cyclin-dependent kinases.

Authors:  John H Doonan; Georgios Kitsios
Journal:  Mol Biotechnol       Date:  2009-01-15       Impact factor: 2.695

5.  Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro.

Authors:  Y Zhu; T Pe'ery; J Peng; Y Ramanathan; N Marshall; T Marshall; B Amendt; M B Mathews; D H Price
Journal:  Genes Dev       Date:  1997-10-15       Impact factor: 11.361

6.  Human and rodent transcription elongation factor P-TEFb: interactions with human immunodeficiency virus type 1 tat and carboxy-terminal domain substrate.

Authors:  Y Ramanathan; S M Reza; T M Young; M B Mathews; T Pe'ery
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

7.  CDK9 is constitutively expressed throughout the cell cycle, and its steady-state expression is independent of SKP2.

Authors:  Judit Garriga; Sabyasachi Bhattacharya; Joaquim Calbó; Renée M Marshall; May Truongcao; Dale S Haines; Xavier Graña
Journal:  Mol Cell Biol       Date:  2003-08       Impact factor: 4.272

Review 8.  Overview of CDK9 as a target in cancer research.

Authors:  Fatima Morales; Antonio Giordano
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

Review 9.  P-TEFb goes viral.

Authors:  Justyna Zaborowska; Nur F Isa; Shona Murphy
Journal:  Inside Cell       Date:  2015-11-25

10.  CDK9 inhibition strategy defines distinct sets of target genes.

Authors:  Judit Garriga; Xavier Graña
Journal:  BMC Res Notes       Date:  2014-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.